tbuckley/cabot-search huggingface dataset:
Use of electronic medical records on cancer screening rates: The proactive office encounter.
Authors: Joanne E. Schottinger, Kristen L. Andrews, Gail X. Lindsay, Michael H. Kanter
Journal: Journal of Clinical Oncology (2012)

289 Background: The Southern California Permanente Medical Group cares for a diverse population of 3.5 million members. An electronic medical record supports the care of patients at each outpatient and inpatient encounter. In the US, only about 55% of Americans receive recommended preventive care services. Methods: The Proactive Office Encounter (POE) was developed to proactively address care gaps in preventive or chronic care needs at the point of service with every visit to either primary or specialty care. Prior to a visit, the staff identify missing labs or screening procedures and provides the patient with pre-visit instructions. With a standardized workflow and checklist used during any office visit, care gaps are identified from decision support tools in the electronic record and office staff pend necessary orders to the physician. The room is prepared for any procedures necessary (Pap), iFOBT kits are made ready for use if indicated, and on exiting, the patient receives an after visit summary that includes any necessary follow up instructions. Successful Completion Opportunity Reports are produced for every department to measure the improvement of closing care gaps. A small financial incentive is applied for specialists for these successful comp-letions (P4P). Back office work flow reports measure the elements of POE at the individual staff level. Performance on screening rates is reported bimonthly for feedback. Results: Within two years of implementation, pre and post POE cancer screening rates increased from 85.6 to 88.7 (3.1%) for breast cancer; 82.0 to 86.6 (4.6%) for cervical cancer; and 52.5 to 69.7 (17.4%) for colorectal cancer. Rates for advising smokers to quit smoking increased from 53 to 68 (15%). Conclusions: Use of evidence-based logic integrated in an electronic medical record combined with standard work flows deployed in primary and specialty care reliably ensures that patients receive needed services at every visit. This contributed to sharp rises in preventive care quality measures. Care shifts from being reactive to team-based and proactive and is no longer dependent on a physician remembering all the needed elements of care.
53P Update results of a novel assay for the detection of methylated CpGs from sputum to screen patients with lung cancer
Authors: T. Nagasaka, A. Nyuya, T. Toshima, T. Kawai, K. Yasui, K. Kimura, Y. Mori, Y. Umeda, H. Kishimoto, T. Fujiwara
Journal: Annals of Oncology (2016)
Cariprazine versus risperidone monotherapy for treatment of predominant negative symptoms in patients with schizophrenia: a randomised, double-blind, controlled trial
Authors: György Németh, István Laszlovszky, Pál Czobor, Erzsébet Szalai, Balázs Szatmári, Judit Harsányi, Ágota Barabássy, Marc Debelle, Suresh Durgam, István Bitter, Stephen Marder, W Wolfgang Fleischhacker
Journal: The Lancet (2017)
Pulmonary artery aneurysms and thrombi
Authors: C M J Steendam, A L Diederik, A Dendooven, R J Snijder, G J Herder
Journal: Thorax (2017)

A 19-year-old previously healthy boy was referred to our hospital with fever, progressive coughing, dyspnoea and haemoptysis for 2 weeks. He had lost weight (3 kg) and was experiencing night sweats.

In the past 6 months, he had experienced that his overall condition and training capacity in sports had decreased noticeably.

On examination, he was tachypnoeic and tachycardic with normal blood pressure. Oxygen saturation was 90% with 15 L of oxygen delivered by Venturi mask. There were diminished breathing sounds in the basal segments of the right lung and in the upper paravertebral region. No other abnormalities were identified.

The laboratory results included a mild microcytic anaemia, leucocytosis and elevation of C reactive protein.

CT and conventional studies showed a central mass in …
Unbiased Whole Blood RNA Profiling in Patients With Acute Coronary Syndrome and at Follow-Up
Authors: Maarten Vanhaverbeke, Denise Veltman, Thibault Petit, Sander Trenson, Arief Wibowo, Hilde Gillijns, Jozef Bartunek, Heinrich J Huber, Stefan Janssens, Peter Sinnaeve
Journal: Circulation (2016)
Coronary Events With Lipid-Lowering Therapy: The AFCAPS/TexCAPS Trial
Authors: I. U. Haq
Journal: JAMA (1999)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Gene-environment interaction between lead and Apolipoprotein E4 causes cognitive behavior deficits in mice
Authors: Anna K. Engstrom, Jessica M. Snyder, Nobuyo Maeda, Zhengui Xia
Journal: Molecular Neurodegeneration (2017)

Alzheimer's disease (AD) is characterized by progressive cognitive decline and memory loss. Environmental factors and gene-environment interactions (GXE) may increase AD risk, accelerate cognitive decline, and impair learning and memory. However, there is currently little direct evidence supporting this hypothesis. In this study, we assessed for a GXE between lead and ApoE4 on cognitive behavior using transgenic knock-in (KI) mice that express the human Apolipoprotein E4 allele (ApoE4-KI) or Apolipoprotein E3 allele (ApoE3-KI). We exposed 8-week-old male and female ApoE3-KI and ApoE4-KI mice to 0.2% lead acetate via drinking water for 12 weeks and assessed for cognitive behavior deficits during and after the lead exposure. In addition, we exposed a second (cellular) cohort of animals to lead and assessed for changes in adult hippocampal neurogenesis as a potential underlying mechanism for lead-induced learning and memory deficits. In the behavior cohort, we found that lead reduced contextual fear memory in all animals; however, this decrease was greatest and statistically significant only in lead-treated ApoE4-KI females. Similarly, only lead-treated ApoE4-KI females exhibited a significant decrease in spontaneous alternation in the T-maze. Furthermore, all lead-treated animals developed persistent spatial working memory deficits in the novel object location test, and this deficit manifested earlier in ApoE4-KI mice, with female ApoE4-KI mice exhibiting the earliest deficit onset. In the cellular cohort, we observed that the maturation, differentiation, and dendritic development of adult-born neurons in the hippocampus was selectively impaired in lead-treated female ApoE4-KI mice. These data suggest that GXE between ApoE4 and lead exposure may contribute to cognitive impairment and that impaired adult hippocampal neurogenesis may contribute to these deficits in cognitive behavior. Together, these data suggest a role for GXE and sex differences in AD risk.
LRPAP1 Is a Frequent B-Cell Receptor Antigen in Mantle Cell Lymphoma (MCL)
Authors: Lorenz Thurner, Sylvia Hartmann, Klaus-Dieter Preuss, Natalie Fadle, Maria Kemele, Evi Regitz, Christiane Pott, Rainer-Maria Bohle, Martin-Leo Hansmann, Michael Pfreundschuh
Journal: Blood (2015)
Identification of Novel Tumor-Associated Antigens in Chronic Lymphocytic Leukemia (CLL) by Serological Proteome Analysis (SERPA)
Authors: Marta Coscia, Valentina Griggio, Michela Capello, Candida Vitale, Federica Linty, Paola Cappello, Giorgia Mandili, Barbara Castella, Myriam Foglietta, Micol Rigoni, Patrizia Sciancalepore, Marta Robino, Marina Ruggeri, Daniela Drandi, Paola Omedè, Marco Ladetto, Francesco Novelli, Mario Boccadoro, Massimo Massaia
Journal: Blood (2012)
Development of open-access mock 510(k) regulatory documents on multiplex proteomic technologies.
Authors: Emily Boja, Tara Hiltke, Chris Kinsinger, Mehdi Mesri, Robert Rivers, Henry Rodriguez
Journal: Journal of Clinical Oncology (2012)

99 Background: Proteome-based biomarker science is progressing slowly for a variety of factors, including a lack of dialogue early in the discovery/development process with regulatory agencies such as the Food and Drug Administration (FDA). Although high-throughput multiplex proteomic-based technologies have the potential to accurately measure proteins of clinical significance in complex human matrices, regulatory approval for these analytical technologies have not been explored. Methods: To address this gap, investigators from the National Cancer Institute’s Clinical Proteomic Tumor Analysis Consortium (CPTAC) held a forward-thinking workshop, involving clinical laboratories, instrument manufacturers, researchers, and FDA representatives in order to streamline the regulatory approval of protein-based multiplex platforms. Results: Outcomes included a peer-reviewed workshop report published in special proteomics issue of Clinical Chemistry, and first-of-its-kind open access mock 510(k) regulatory documents (based on two most commonly applied quantitative proteomic technologies: multiplex mass spectrometry-based and multiplex affinity-based platforms) as public community resources (also published in Clinical Chemistry). Conclusions: These open-access documents provide a glimpse of the FDA’s perspective of novel approaches to in vitro diagnostics of multiplex protein assays and the process of premarket review. Therefore, these resources should enable others to focus on aspects of the process carefully monitored by the FDA, observe a format that is acceptable to the agency, and understand the iterative nature of review.
Cytotoxic T-lymphocyte-associated protein 4-Ig effectively controls immune activation and inflammatory disease in a novel murine model of leaky severe combined immunodeficiency
Authors: Stéphanie Humblet-Baron, Susann Schönefeldt, Josselyn E. Garcia-Perez, Frédéric Baron, Emanuela Pasciuto, Adrian Liston
Journal: Journal of Allergy and Clinical Immunology (2017)
Epirubicin dose escalation in the treatment of soft tissue sarcoma
Authors: D. A. Rushing, S. K. Quinney, D. J. Murry
Journal: Journal of Clinical Oncology (2004)

9034 Background: Epirubicin (Epi), a topoisomerase II-targeted anthracycline, has been used safely in doses ranging from 75–160 mg/m2 for the treatment of patients (pts) with soft tissue sarcoma (STS). We performed a pharmacokinetic (PK) dose-response study in pts with unresectable or metastatic STS. Methods: Previously untreated patients (PS 0–1) were given Epi 75 mg/m2. 11 serial blood samples were obtained in 24 hrs after a 10 min Epi IV infusion. Epi concentrations were determined using a validated LC-MS assay and Epi area under the concentration-time curve (EAUC) was calculated. After 2 cycles of chemotherapy pts with EAUC<2133 (ng-hr/ml) and progressive disease (PD) were dose escalated in order to achieve a target EAUC of 3200 ng-hr/ml. Further patient accrual required 4 responses by RECIST criteria in 14 patients treated by dose escalation Results: A total of 18 pts (9 male, 9 female, median age 54 years) were enrolled. Treatment with Epi 75 mg/m2 produced a median EAUC= 1538(range 1140–3677). 3 pts treated with Epi 75 mg/m2 had AUC>2133 and could not be dose escalated, 1 pt died before response could be assessed. 13 pts had dose escalation; PK values are available for 11 pts. Median EAUC was 3125 (range 2533 - 3619). Toxicities included Grade III/IV hematologic toxicity in 8 pts and G.I. Grade III toxicity in 4 pts. . No responses by RECIST criteria occured at 75mg/m2 . 9 pts had PD, but 1 pt had minor response (MR), 4 had stable disease (SD), 1 of theses was negative by PET scan. Dose escalation produced 1 partial response (PR), 5 SD with 3 PET neg, and 5 PD. All pts with SD or minimal response (MR) at the lower dose had at least SD or MR at the higher dose. 1 pt with AUC<2133 ng.h/mL was PET negative vs 1 PR, 3 PET negative with AUC>2133. Conclusions: EAUC increased linearly with dose increases, however, there was substantial inter-patient variability in the doses required to achieve the desired EAUC. Doses of Epi that result in EAUC<2133 appear inadequate. Further study is indicated if PET criteria are proven to be reliable to judge response. Epi dose escalation produced significant clinical responses in some STS pts with notable hematological / GI toxicities Author Disclosure Employment or Leadership Consultant or Advisory Stock Ownership Honoraria Research Funding Expert Testimony Other Remuneration Pfizer Pharmacia
Conserved IKAROS-regulated genes associated with B-progenitor acute lymphoblastic leukemia outcome
Authors: Matthew T. Witkowski, Yifang Hu, Kathryn G. Roberts, Judith M. Boer, Mark D. McKenzie, Grace J. Liu, Oliver D. Le Grice, Cedric S. Tremblay, Margherita Ghisi, Tracy A. Willson, Martin A. Horstmann, Iannis Aifantis, Luisa Cimmino, Seth Frietze, Monique L. den Boer, Charles G. Mullighan, Gordon K. Smyth, Ross A. Dickins
Journal: The Journal of Experimental Medicine (2017)

Genetic alterations disrupting the transcription factor IKZF1 (encoding IKAROS) are associated with poor outcome in B lineage acute lymphoblastic leukemia (B-ALL) and occur in &amp;gt;70% of the high-risk BCR-ABL1+ (Ph+) and Ph-like disease subtypes. To examine IKAROS function in this context, we have developed novel mouse models allowing reversible RNAi-based control of Ikaros expression in established B-ALL in vivo. Notably, leukemias driven by combined BCR-ABL1 expression and Ikaros suppression rapidly regress when endogenous Ikaros is restored, causing sustained disease remission or ablation. Comparison of transcriptional profiles accompanying dynamic Ikaros perturbation in murine B-ALL in vivo with two independent human B-ALL cohorts identified nine evolutionarily conserved IKAROS-repressed genes. Notably, high expression of six of these genes is associated with inferior event–free survival in both patient cohorts. Among them are EMP1, which was recently implicated in B-ALL proliferation and prednisolone resistance, and the novel target CTNND1, encoding P120-catenin. We demonstrate that elevated Ctnnd1 expression contributes to maintenance of murine B-ALL cells with compromised Ikaros function. These results suggest that IKZF1 alterations in B-ALL leads to induction of multiple genes associated with proliferation and treatment resistance, identifying potential new therapeutic targets for high-risk disease.
Subcutaneous C1-Esterase Inhibitor [C1-INH(SC)] to Prevent Hereditary Angioedema (HAE) Attacks: Subject and Investigator Assessments from the Compact Trial
Authors: Hilary J. Longhurst, Huamin Henry Li, Marc A. Riedl, Timothy J. Craig, Avner Reshef, Henriette Farkas, Henrike Feuersenger, Daniel Wood, Douglas Watson, Ingo Pragst
Journal: Journal of Allergy and Clinical Immunology (2017)
Exposure to low dose computed tomography for lung cancer screening and risk of cancer: secondary analysis of trial data and risk-benefit analysis
Authors: Cristiano Rampinelli, Paolo De Marco, Daniela Origgi, Patrick Maisonneuve, Monica Casiraghi, Giulia Veronesi, Lorenzo Spaggiari, Massimo Bellomi
Journal: BMJ (2017)

<b>Objective</b>&nbsp;To estimate the cumulative radiation exposure and lifetime attributable risk of cancer incidence associated with lung cancer screening using annual low dose computed tomography (CT). <b>Design</b>&nbsp;Secondary analysis of data from a lung cancer screening trial and risk-benefit analysis. <b>Setting</b>&nbsp;10 year, non-randomised, single centre, low dose CT, lung cancer screening trial (COSMOS study) which took place in Milan, Italy in 2004-15 (enrolment in 2004-05). Secondary analysis took place in 2015-16. <b>Participants</b>&nbsp;High risk asymptomatic smokers aged 50 and older, who were current or former smokers (≥20 pack years), and had no history of cancer in the previous five years. <b>Main outcome measures</b>&nbsp;Cumulative radiation exposure from low dose CT and positron emission tomography (PET) CT scans, calculated by dosimetry software; and lifetime attributable risk of cancer incidence, calculated from the <i>Biological Effects of Ionizing Radiation VII</i> (BEIR VII) report. <b>Results</b>&nbsp;Over 10 years, 5203 participants (3439 men, 1764 women) underwent 42 228 low dose CT and 635 PET CT scans. The median cumulative effective dose at the 10th year of screening was 9.3 mSv for men and 13.0 mSv for women. According to participants’ age and sex, the lifetime attributable risk of lung cancer and major cancers after 10 years of CT screening ranged from 5.5 to 1.4 per 10 000 people screened, and from 8.1 to 2.6 per 10 000 people screened, respectively. In women aged 50-54, the lifetime attributable risk of lung cancer and major cancers was about fourfold and threefold higher than for men aged 65 and older, respectively. The numbers of lung cancer and major cancer cases induced by 10 years of screening in our cohort were 1.5 and 2.4, respectively, which corresponded to an additional risk of induced major cancers of 0.05% (2.4/5203). 259 lung cancers were diagnosed in 10 years of screening; one radiation induced major cancer would be expected for every 108 (259/2.4) lung cancers detected through screening. <b>Conclusion</b>&nbsp;Radiation exposure and cancer risk from low dose CT screening for lung cancer, even if non-negligible, can be considered acceptable in light of the substantial mortality reduction associated with screening.
Burkitt Lymphoma Genome Sequencing Project (BLGSP): Introduction
Authors: Daniela S Gerhard, Bruno Grande, Nicholas Griner, Corey Casper, Sarah E. Gerdts, Abraham Omoding, Jackson Orem, Sam M Mbulaiteye, Martin D. Ogwang, Steven J. Reynolds, Kishor Bhatia, Leona Ayers, John K Choi, Charles G. Mullighan, John T. Sandlund, Thomas B. Alexander, Jeremy S. Abramson, Thomas G. Gross, Ariela Noy, Jeffrey Bethony, Fabio Leal, Timothy C Greiner, Elaine S. Jaffe, Nancy Lee Harris, Julie M. Gastier-Foster, Jay Bowen, Benjamin Hanf, Roland Schmitz, Jean-Paul Martin, Marie-Reine Martin, John D. Irvin, Ellen Miller, Patee Gesuwan, Leandro C. Hermida, Tanja M. Davidsen, Andrew J. Mungall, Yussanne Ma, Marco A. Marra, Ryan D. Morin, Louis M. Staudt
Journal: Blood (2016)
Recovery of chemotherapy-induced left ventricular dysfunction in cancer survivors.
Authors: Anecita P. Fadol, Jose Banchs, Saamir Hassan, Jean-Bernard Durand, Valerie Shelton, Lisa A. Smith, Bryan Fellman, Amy Zhuang, Edward T.H. Yeh
Journal: Journal of Clinical Oncology (2016)

136 Background: Chemotherapy-induced left ventricular dysfunction (CILVD) leading to heart failure (HF) is a clinical problem of emerging importance particularly with the 14.5 million cancer survivors who are alive in the United States today, and projected to increase to almost 19 million in 2024. Many of these survivors have received cardiotoxic anticancer agents such as anthracycline and trastuzumab. Research showed that those exposed to anthracyclines are expected to have some degree of cardiac dysfunction 10 to 20 years after treatment and 5% of those patients will develop overt HF. This pilot study investigated whether cancer survivors with CILVD who achieved recovery of cardiac function will maintain their left ventricular ejection fraction (LVEF) if HF medications were discontinued. Methods: We conducted a prospective pilot study on 20 cancer survivors with history of CILVD with recovered cardiac function. HF medications were weaned off in a stepwise process per protocol. Cardiac function was monitored with LVEF measurement per echocardiography and cardiac biomarkers performed at baseline, 2, 4 and 6 months. Patients monitor their heart rate, blood pressure, and symptoms and reported changes based on set parameters. Results: Cancer survivors who maintained their LVEF after discontinuation of HF medications were younger (mean age 47.9 years SD+12.0), 65% female, 55% breast cancer survivors, with no history ofischemic heart disease, hypertension, diabetes mellitus and cardiac dysrhythmias. Chemotherapeutic agents (mean dose) used in the treatment of these patients include doxorubicin (363 mg/m 2 ), epirubicin (527mg /m 2 ), cyclophosphamide (5062 mg), and trastuzumab (6317 mg). There was no significant change from baseline measurements of LVEF and global longitudinal strain (GLS) of 55.1% (± 3.7) GLS of -18.3% (± 2.7) prior to weaning the HF medication to 56% (± 1.6) GLS of -18.2% (± 2.3). after complete withdrawal of HF medications. Conclusions: With the increasing number of young cancer survivors, CILVD may become a frequent clinical issue. Clearly, there is a need to examine the safety of withdrawing HF medications in cancer survivors with CILVD and if lifelong therapy with HF medications is necessary.
Molecular Screening for Hepatitis B and Hepatitis C Viruses in Allogeneic Hematopoietic Stem Cell Transplantation– a Pilot Study
Authors: Malgorzata Sobczyk-Kruszelnicka, Miroslaw Markiewicz, Agata Wieczorkiewicz-Kabut, Agnieszka Wieclawek, Anna Soja, Monika Dzierzak-Mietla, Anna Koclega, Krzysztof Bialas, Slawomira Kyrcz-Krzemien
Journal: Blood (2012)